Bristol-Myers Seeks FDA Approval of CAR T-cell Therapy Liso-Cel for Aggressive Large B-cell Lymphomas
News
Bristol-Myers Squibb has asked the U.S. Food and Drug Administration (FDA) to approve its investigational CAR T-cell therapy lisocabtagene maraleucel (liso-cel) for people with large B-cell lymphoma who received at ... Read more